Brokerages Set $1.00 Target Price for GTx Inc. (GTXI)
GTx Inc. (NASDAQ:GTXI) has earned a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.
Brokers have set a one year consensus price objective of $1.00 for the company and are expecting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also given GTx an industry rank of 109 out of 265 based on the ratings given to related companies.
A number of equities research analysts have issued reports on GTXI shares. Jefferies Group reaffirmed a “hold” rating and set a $1.00 price objective on shares of GTx in a report on Friday, September 9th. Zacks Investment Research raised shares of GTx from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/brokerages-set-1-00-target-price-for-gtx-inc-gtxi.html
A hedge fund recently raised its stake in GTx stock. BVF Inc. IL raised its position in shares of GTx Inc. (NASDAQ:GTXI) by 3.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,512,000 shares of the biopharmaceutical company’s stock after buying an additional 348,864 shares during the period. GTx accounts for 1.4% of BVF Inc. IL’s portfolio, making the stock its 21st largest position. BVF Inc. IL owned 8.12% of GTx worth $5,756,000 at the end of the most recent quarter. Institutional investors own 10.77% of the company’s stock.
Shares of GTx (NASDAQ:GTXI) traded up 1.916% during midday trading on Wednesday, hitting $0.835. 73,571 shares of the company traded hands. The stock has a 50 day moving average of $0.72 and a 200-day moving average of $0.65. GTx has a 52 week low of $0.29 and a 52 week high of $1.15. The stock has a market capitalization of $118.50 million, a PE ratio of 5.030 and a beta of 2.36.
GTx (NASDAQ:GTXI) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Equities analysts forecast that GTx will post ($0.12) earnings per share for the current fiscal year.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.